Navigation Links
Czura Thornton Announces Intention to Acquire Global Central Laboratory Business of MDS Pharma Services
Date:10/9/2009

LONDON, Oct. 9 /PRNewswire/ -- Private investment firm Czura Thornton today announced it has signed an agreement to acquire the global central laboratory ('GCL') operations of MDS Pharma Services, a business unit of MDS Inc (NYSE: MDZ; TSX: MDS).

GCL, to announce a new brand shortly, provides a comprehensive range of late-stage laboratory and electrocardiogram services supporting clinical trials globally. The business' proprietary leading edge Apollo CLPM(TM) (Central Lab Protocol Management) system offers clients real-time access to study data from around the world. GCL employs 600 people at accredited facilities in Beijing, Hamburg, North Brunswick (New Jersey), Paris, Singapore and Toronto.

In a joint statement, Czura Thornton's founders Tony Czura and Nick Thornton said: "We are delighted to be acquiring MDS's global central laboratory platform and the deep expertise of the people there. Combined with our focus on the consistent delivery of high quality service and the flexibility and responsiveness that private ownership allows, we look forward to seeing renewed strength and growth in the business." They added that, "While we see excellent opportunities for collaboration with Chiltern, a leading CRO also owned by Czura Thornton, the two entities will operate independently."

The transaction is expected to close in the fourth quarter of 2009 and is subject to customary approvals and closing conditions. In addition, the sale of the Central Labs operations in France and Germany is subject to review and consultation with the applicable Works Councils in accordance with labor laws in those countries.

"We are pleased that the agreement with Czura Thornton creates opportunities to build the Central Labs business, which includes world-class facilities and highly skilled people focused on delivering superior client service," said Stephen P. DeFalco, President and Chief Executive Officer of MDS Inc.

About Czura Thornton: Czura Thornton is a private investment group that was founded by Tony Czura and Nick Thornton in 2003. The group, which owns leading CRO Chiltern (www.chiltern.com), has interests in the life sciences, international trade, property and automotive sectors. In particular Messrs Czura and Thornton have extensive international experience in the laboratory and CRO sectors. For further information see www.czurathornton.com.

Contact: Zareena Chattoo; +44 1753 216 611 (U.K.)

SOURCE Czura Thornton


'/>"/>
SOURCE Czura Thornton
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients
2. Kimberly-Clark Announces Definitive Agreement to Acquire I-Flow Corporation
3. NIAID announces vaccine adjuvant discovery contracts
4. STEMCELL Technologies Inc. Announces Direct Distribution to Spain
5. ONRAD Announces New Partnership with La Maestra Community Health Centers of San Diego, CA
6. NCG Medical Announces Its Participation in Preliminary ARRA 2011 Certification Program
7. Institute for Liberty Announces the Launch of Keeping Small Business Healthy
8. PAREXEL Announces Date of First Quarter Fiscal Year 2010 Earnings Release and Conference Call
9. Medical Travel Company Satori World Medical Announces Relationship with Managing General Underwriter GreenWood International Insurance Services (GWI)
10. Cord Blood America Announces Debt Reduction Tally: $8.7 Million in 2009; $3.7 Million in Third Quarter
11. Tranziger Announces Formation of Global Advisory & Development Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... London UK (PRWEB) , ... June 27, 2017 , ... ... a clinical study is whether they can trust the sponsor to pay them correctly ... vital that sponsors and CROs establish payment strategies that encourage sites to work on ...
(Date:6/27/2017)... ... , ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation ... and Affordable Care Act (ACA), would result in 22 million Americans losing their health ... More than 20 million Americans have gained health insurance under the ACA, and from ...
(Date:6/27/2017)... ... 27, 2017 , ... A January 18th article on medGadget reports ... billion by the year 2024 according to a new report. The article also notes ... from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says ...
(Date:6/27/2017)... New York, NY (PRWEB) , ... June 27, ... ... communications and marketing experts to contribute to an upcoming case studies guidebook. This ... or her organization. , This book will include articles, case studies and how-to’s ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... -- Less than a month ago, amateur hackers executed an ... hospital networks, in over 150 countries. The ... online extortion attempts ever recorded. With the increasing complexity ... that providers understand where the risks lie, and how ... many other very real cyber threats.  ...
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology: